ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
-0.43%
Brent Oil
83.76
0.67%
Bitcoin
66,939.03
2.61%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vir Biotechnology Inc (VIR)

  7. Vir Biotechnology Inc (VIR) Noticias

VIR

Vir Biotechnology (VIR)

Vir Biotechnology Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VIR
FechaHoraFuenteTítuloSímboloCompañía
14/05/202415:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRVir Biotechnology Inc
02/05/202415:05Business WireVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
30/04/202415:05Business WireVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024NASDAQ:VIRVir Biotechnology Inc
18/04/202407:00Business WireVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsNASDAQ:VIRVir Biotechnology Inc
11/04/202415:30Business WireVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024NASDAQ:VIRVir Biotechnology Inc
05/03/202407:05Business WireVir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of ScheduleNASDAQ:VIRVir Biotechnology Inc
26/02/202418:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
26/02/202415:27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRVir Biotechnology Inc
26/02/202415:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRVir Biotechnology Inc
23/02/202407:05Business WireVir Biotechnology to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:VIRVir Biotechnology Inc
22/02/202415:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
22/02/202415:05Business WireVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
20/02/202415:30Business WireVir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical OfficerNASDAQ:VIRVir Biotechnology Inc
13/02/202416:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VIRVir Biotechnology Inc
01/02/202415:05Business WireVir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024NASDAQ:VIRVir Biotechnology Inc
14/12/202304:59IH Market NewsApple Stocks Reach Record, Adobe Faces Stock Drops, Berkshire Hathaway Increases Stake in OXY, and MoreNASDAQ:VIRVir Biotechnology Inc
13/12/202315:05Business WireVir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value CreationNASDAQ:VIRVir Biotechnology Inc
06/12/202315:05Business WireVir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
13/11/202307:00Business WireVir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023NASDAQ:VIRVir Biotechnology Inc
10/11/202307:00Business WireVir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023NASDAQ:VIRVir Biotechnology Inc
08/11/202307:05Business WireVir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™NASDAQ:VIRVir Biotechnology Inc
03/11/202315:33Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VIRVir Biotechnology Inc
03/11/202315:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRVir Biotechnology Inc
02/11/202315:05Business WireVir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
30/10/202307:00Business WireVir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific OfficerNASDAQ:VIRVir Biotechnology Inc
12/10/202315:05GlobeNewswire Inc.Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) ConferenceNASDAQ:VIRVir Biotechnology Inc
11/10/202307:00GlobeNewswire Inc.Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023NASDAQ:VIRVir Biotechnology Inc
05/10/202315:30GlobeNewswire Inc.Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:VIRVir Biotechnology Inc
03/10/202306:59GlobeNewswire Inc.Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease ThreatsNASDAQ:VIRVir Biotechnology Inc
20/09/202307:00GlobeNewswire Inc.Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIVNASDAQ:VIRVir Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:VIR

Su Consulta Reciente

USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
ADDYY
Adidas (QX)
NYSE
DIS
Walt Disney
NYSE
VZ
Verizon Communications
NYSE
KO
Coca Cola
SPI
SP500
S&P 500
USOTC
RHHBY
Roche (QX)
NASDAQ
MSFT
Microsoft
NASDAQ
AMZN
Amazon.com
FX
USDMXN
US Dollar vs MXN
AMEX
XLF
Financial Select Sector
FX
EURMXN
Euro vs MXN
NYSE
CVX
Chevron
COIN
BTCUSD
Bitcoin
CCOM
OILBRENT
Brent Oil
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados